Agios Pharmaceuticals is halting development of tebapivat, its experimental sickle cell disease drug, after mid-stage results failed to impress.
The company said the Phase 2 candidate “did not demonstrate the level of differentiation required to support continued development.” In plain terms: the data weren't strong enough to justify pushing a crowded-field drug toward the finish line. Agios shares fell about 6.5% to roughly $37.50 on the news.
A setback in a tough field
Tebapivat was designed as a next-generation pyruvate kinase activator — the same enzyme-boosting approach behind Agios's already-approved drug mitapivat. By activating pyruvate kinase, these therapies aim to improve the health and survival of red blood cells, which are damaged in sickle cell disease.
The timing stings competitively: rival Novo Nordisk recently reported positive Phase 3 results for its own sickle cell enzyme activator, leaving Agios without the differentiation it had hoped tebapivat would provide.
What's left in the pipeline
Agios isn't out of sickle cell entirely. Its approved drug mitapivat is still being developed for the condition, with an FDA decision expected by November 1. The company also continues to pursue earlier-stage research. Sickle cell has proven a difficult area for drugmakers, and tebapivat's exit is another reminder that promising mechanisms don't always translate into differentiated medicines.